Journal of the National Cancer Institute
-
J. Natl. Cancer Inst. · Sep 2012
Review Meta AnalysisNeurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review.
The addition of neurokinin-1 receptor (NK1R) antagonists to antiemetic regimens has substantially reduced chemotherapy-induced nausea and vomiting (CINV). We sought to systematically review the overall impact of NK1R antagonists on CINV prevention. ⋯ NK1R antagonists increased CINV control in the acute, delayed, and overall phases. They are effective for both moderately and highly emetogenic chemotherapy regimens. Their use might be associated with increased infection rates; however, additional appraisal of specific data from RCTs is needed.
-
J. Natl. Cancer Inst. · Sep 2012
Comparative StudyRisk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.
Clinical trials demonstrated that women treated for breast cancer with anthracycline or trastuzumab are at increased risk for heart failure and/or cardiomyopathy (HF/CM), but the generalizability of these findings is unknown. We estimated real-world adjuvant anthracycline and trastuzumab use and their associations with incident HF/CM. ⋯ Anthracycline and trastuzumab were primarily used in younger, healthier women and associated with increased HF/CM risk compared with no chemotherapy. This population-based observational study complements findings from clinical trials on cancer treatment safety.